With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint inhibitors that reactivate the immune system to target cancer. These therapies show the most promise in triple-negative breast cancer, which has the highest mutation load. While chemo remains the foundation, ongoing research is pushing for more targeted, less toxic alternatives. Tiersten emphasizes that with today’s arsenal, patients are living longer, better lives—and the pipeline is only getting stronger.